Related Experiment Videos
Suppression of ACTH secretion by synthetic MSH-release inhibiting factor Pro-Leu-Gly-NH2 in Addison's disease
Abstract:
The regulation of release of MSH and ACTH seems to be closely related. The effect of Pro-Leu-Gly-NH2, the most active MSH-release inhibiting factor (MIF), was investigated on ACTH-hypersecretion in six patients suffering from primary adrenocortical insufficiency. MIF was infused at constant rates with stepwise increase in concentration (0.25 mg, 2.5 mg, 25.0 mg/30 min). Plasma ACTH-levels were measured radioimmunologically at 10 minutes intervals. In four cases there was a remarkable decrease (P less than 0.005) in the ACTH plasma level of more than 50% as compared to the elevated starting levels of 800 to 1400 pg/ml. It is concluded that under certain circumstances MIF could play a role in the regulation of ACTH-secretion.
Insights
Pro-Leu-Gly-NH2, a MSH-release inhibiting factor (MIF), significantly reduced ACTH hypersecretion in patients with primary adrenocortical insufficiency. This suggests MIF may regulate ACTH secretion under specific conditions.
Area of Science:
- Endocrinology
- Neuroendocrinology
- Hormone Regulation
Background:
- The release of melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) appears interconnected.
- Primary adrenocortical insufficiency is characterized by elevated ACTH levels.
- MSH-release inhibiting factor (MIF) is known to inhibit MSH release.
Purpose of the Study:
- To investigate the effect of MIF on ACTH hypersecretion.
- To explore the potential role of MIF in regulating ACTH secretion.
- To assess MIF's impact in patients with primary adrenocortical insufficiency.
Main Methods:
- Infusion of MIF (Pro-Leu-Gly-NH2) at increasing concentrations in six patients.
- Radioimmunological measurement of plasma ACTH levels at 10-minute intervals.
- Comparison of ACTH levels before and during MIF infusion.
Main Results:
- A significant decrease (P < 0.005) in plasma ACTH levels exceeding 50% was observed in four out of six patients.
- The reduction was noted compared to baseline elevated ACTH levels ranging from 800 to 1400 pg/ml.
- MIF demonstrated a notable impact on suppressing hypersecreted ACTH.
Conclusions:
- MIF (Pro-Leu-Gly-NH2) can effectively reduce ACTH hypersecretion in certain clinical contexts.
- These findings suggest a potential role for MIF in the physiological regulation of ACTH secretion.
- Further research is warranted to elucidate the precise mechanisms and clinical implications of MIF in ACTH regulation.